Adimab

Valuation $1B

About Adimab

Adimab is an antibody discovery and optimization platform, developing full-length human Immunoglobulin Gs.
Headquarters Adimab, Lebanon
Founded 2007-05-01
Industry Biotechnology, Collaboration, Health Care, Therapeutics
Last Funding Type Series Unknown
Valuation 1
Total Funding $45.48 million dollars
IPO Status Private

Financial

Adimab may be growing as indicated by the recent announcement of a substantial expansion of its research campus. This expansion suggests an increase in operational capacity and potentially a broadening of its research and development activities. Such a move typically reflects a positive trajectory in a company's growth, as it often requires significant investment and implies confidence in future business prospects. The expansion of a research campus in the biotechnology industry, where Adimab operates, is a strong indicator of growth, as it enables the company to enhance its capabilities in antibody discovery and optimization.

Adimab is focused on the discovery and optimization of antibodies, particularly full-length human Immunoglobulin Gs. Relevant patents include the development of anti-coagulation factor XI antibodies, which inhibit blood coagulation and associated thrombosis, and the creation of rationally designed, synthetic antibody libraries that reflect the preimmune repertoire. These efforts highlight Adimab's commitment to advancing antibody technology through innovative library design and targeted therapeutic applications.

Funding Rounds 8
Number of Lead Investors 3
Total Funding Amount  $45.48 million dollars
Number of Investors 6

Related Angels

Georges Harik
View profile